View in EDS HTML Full Text PDF Full Text

A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.

Saved in:
Bibliographic Details
Title: A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Authors: Mayer EL; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA., Tayob N; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA., Ren S; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA., Savoie JJ; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA., Spigel DR; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.; Sarah Cannon Research Institute, Nashville, TN, USA., Burris HA 3rd; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.; Sarah Cannon Research Institute, Nashville, TN, USA., Ryan PD; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.; Texas Oncology, The Woodlands, TX, USA., Harris LN; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.; National Cancer Institute, Bethesda, MD, USA., Winer EP; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.; Yale Cancer Center, New Haven, CT, USA., Burstein HJ; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. Hal_Burstein@dfci.harvard.edu.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Feb; Vol. 204 (1), pp. 123-132. Date of Electronic Publication: 2023 Nov 29.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38019444
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Mayer+EL%22">Mayer EL</searchLink>; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.<br /><searchLink fieldCode="AU" term="%22Tayob+N%22">Tayob N</searchLink>; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.<br /><searchLink fieldCode="AU" term="%22Ren+S%22">Ren S</searchLink>; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.<br /><searchLink fieldCode="AU" term="%22Savoie+JJ%22">Savoie JJ</searchLink>; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.<br /><searchLink fieldCode="AU" term="%22Spigel+DR%22">Spigel DR</searchLink>; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.; Sarah Cannon Research Institute, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Burris+HA+3rd%22">Burris HA 3rd</searchLink>; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.; Sarah Cannon Research Institute, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Ryan+PD%22">Ryan PD</searchLink>; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.; Texas Oncology, The Woodlands, TX, USA.<br /><searchLink fieldCode="AU" term="%22Harris+LN%22">Harris LN</searchLink>; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.; National Cancer Institute, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Winer+EP%22">Winer EP</searchLink>; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.; Yale Cancer Center, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Burstein+HJ%22">Burstein HJ</searchLink>; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. Hal_Burstein@dfci.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228111104%22">Breast cancer research and treatment</searchLink> [Breast Cancer Res Treat] 2024 Feb; Vol. 204 (1), pp. 123-132. <i>Date of Electronic Publication: </i>2023 Nov 29.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Kluwer+Academic%22">Kluwer Academic </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8111104 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-7217 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676806%22">01676806 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res Treat <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38019444
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10549-023-07167-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 123
    Titles:
      – TitleFull: A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mayer EL
      – PersonEntity:
          Name:
            NameFull: Tayob N
      – PersonEntity:
          Name:
            NameFull: Ren S
      – PersonEntity:
          Name:
            NameFull: Savoie JJ
      – PersonEntity:
          Name:
            NameFull: Spigel DR
      – PersonEntity:
          Name:
            NameFull: Burris HA 3rd
      – PersonEntity:
          Name:
            NameFull: Ryan PD
      – PersonEntity:
          Name:
            NameFull: Harris LN
      – PersonEntity:
          Name:
            NameFull: Winer EP
      – PersonEntity:
          Name:
            NameFull: Burstein HJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2024 Feb
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1573-7217
          Numbering:
            – Type: volume
              Value: 204
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Breast cancer research and treatment
              Type: main
ResultId 1